Pangea Biomed

The ENLIGHT platform has demonstrated retrospective validation as a predictor of patient response to both targeted therapies and immunotherapies across multiple cancer types. It has identified novel biomarkers of resistance/sensitivity (e.g., PARP inhibitors in BRCA+ PDAC) and enabled exceptional case reports where its predictions led to complete remission against standard biomarker expectations. Prospective clinical trial validation efforts are underway with academic collaborators such as Sheba Medical Center.

The company’s technology can use either NGS or digital pathology images as input—potentially democratizing access to precision oncology globally by reducing reliance on expensive sequencing infrastructure.

No direct therapeutic programs—focuses on enabling drug development/clinical trial design/patient stratification through its computational platforms.

Pipeline_breadth/Pipeline details below reflect this focus.